Overview

Detailed Summary

JFL Life Sciences Limited, established in 2010, specializes in the manufacturing and marketing of pharmaceutical products, including dry powder injections and various tablets and capsules.
The company has a wide reach with its products distributed across India and exported to 10 countries, including parts of Africa, the Middle East, and CIS nations.
JFL Life Sciences has a robust R&D infrastructure and an FDA-approved manufacturing facility near Ahmedabad, enhancing its competitive edge in the pharmaceutical sector.
Through its IPO in August 2022, JFL Life Sciences raised approximately Rs. 18.16 Crore, aiding its expansion and financial strategy.
The company is strategically registered with health ministries in several countries and uses a stringent quality assurance process for its manufacturing stages.

Sector: Pharmaceuticals
Industry: Pharmaceuticals - Indian - Formulations
Market Cap: 36 Cr
Volatility: Low Risk
P/E Ratio: 7.6
Industry P/E: 42.8
PEG Ratio: 0.5
P/B Ratio: 0.9
52W High: 22.20
52W Low: 10.00

Sales CAGR

1Y: 76.24%
3Y: 34.67%
5Y: 22.15%
10Y: —

Profit CAGR

1Y: 26.06%
3Y: 13.96%
5Y: 63.09%
10Y: —

ROE

TTM: 8.41%
3Y: 9.57%
5Y: 10.86%
10Y: —

ROCE

TTM: 12.26%
3Y: 15.42%
5Y: 17.10%
10Y: —

Technicals

‌

Forecasts

Peers

Symbol	Price	Market Cap	P/E	P/B	Div Yield (%)	ROE (%)	ROCE (%)	ROA (%)
BIOFILCHEM	30.66	50 Cr	18.04	2.34	0.00	13.42	15.83	5.00
PANJON	24.61	43 Cr	105.62	2.51	0.00	4.40	4.69	3.53
VISTAPH	6.42	39 Cr	-3.45	0.88	0.00	-15.00	-13.49	-12.63
JFLLIFE	10.95	36 Cr	7.55	0.86	0.00	8.41	12.26	4.11
SANDUPHQ	34.80	34 Cr	11.49	1.01	2.30	3.69	5.32	2.80
GUJTERC	39.75	31 Cr	-25.88	3.49	0.00	-13.06	39.56	-5.20
MEDIORG	22.90	27 Cr	6.26	0.91	0.00	14.02	13.68	7.49

Financial Statements

AI Powered Summary

Discover detailed, AI-driven financial summaries that break down key metrics, trends, and insights—empowering you to make smarter investment decisions.

Ask AI

Standalone Quarterly Results (in ₹ Crores)

Total Figures

QoQ Changes

Total Figures

	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025
Sales	22	9.54	40	21	12	12	30	27
Expenses	20	6.49	37	20	10	9.66	27	23
Operating Profit	1.55	3.05	2.41	1.35	1.38	1.93	2.92	3.35
OPM %	7.14	31.97	6.10	6.35	11.76	16.65	9.76	12.48
Other Income	0.02	0.00	0.00	0.00	0.00	0.00	0.01	0.01
Interest	0.09	0.26	0.27	0.20	0.33	0.24	0.44	0.38
Depreciation	0.11	0.24	0.24	0.16	0.36	0.26	0.27	0.27
Profit Before Tax	1.37	2.56	1.90	0.99	0.69	1.43	2.22	2.71
Tax %	13.14	25.00	23.68	25.25	88.41	47.55	10.81	25.46
Net Profit	1.19	1.91	1.45	0.74	0.08	0.75	1.97	2.02
EPS in Rs	0.12	—	0.44	—	0.01	0.23	0.60	0.61

Standalone Profit Loss (in ₹ Crores)

Total Figures

YoY Changes

Total Figures

	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	TTM
Sales	32	30	33	34	43	47	82	54
Expenses	30	28	31	28	39	42	74	46
Operating Profit	1.32	1.86	2.16	5.36	3.93	4.54	8.20	7.71
OPM %	4.16	6.17	6.60	15.96	9.17	9.76	9.99	14.25
Other Income	0.00	0.03	0.09	0.89	1.64	0.52	0.01	NaN
Interest	0.75	1.16	1.23	2.08	1.42	0.83	1.08	1.03
Depreciation	0.15	0.24	0.28	0.37	0.43	0.44	0.99	1.02
Profit Before Tax	0.42	0.50	0.75	3.80	3.72	3.80	6.14	5.67
Tax %	28.45	27.48	27.39	26.05	24.46	12.95	32.22	38.62
Net Profit	0.30	0.36	0.54	2.81	2.81	3.31	4.16	3.48
EPS in Rs	—	—	—	—	—	—	—	1.45
Dividend Payout %	0.00	0.00	0.00	0.00	0.00	8.31	0.00	—

Standalone Balance Sheet (in ₹ Crores)

Total Figures

YoY Changes

Total Figures

	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Equity Capital	0.42	0.42	0.50	8.02	11	11	33
Reserves	4.59	4.95	6.38	3.27	21	25	6.46
Borrowings	8.41	9.32	17	16	7.18	5.69	11
Other Liabilities	2.73	9.63	5.32	21	9.61	15	22
Total Liabilities	16	24	29	48	49	57	72
Fixed Assets	2.48	5.05	6.50	7.13	6.80	12	12
CWIP	0.04	0.00	0.00	0.00	0.00	0.00	0.00
Investments	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Other Assets	14	19	23	41	42	44	60
Total Assets	16	24	29	48	49	57	72

Standalone Cash Flows (in ₹ Crores)

Total Figures

YoY Changes

Total Figures

	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Cash from Operating Activity	-3.00	3.21	-5.87	2.32	-9.07	8.36	-3.53
Cash from Investing Activity	-0.61	-2.76	-1.64	-0.71	0.87	-6.07	-0.01
Cash from Financing Activity	3.61	-0.19	7.25	-1.46	8.07	-2.31	3.54
Net Cash Flow	-0.00	0.27	-0.26	0.15	-0.13	-0.03	-0.00

Shareholdings

Shareholding History

Quarterly

Yearly

Quarterly

	Apr 2022	Sep 2022	Dec 2022	Mar 2023	Sep 2023	Mar 2024	Sep 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025
Promoters	92.52%	67.47%	67.47%	67.47%	67.47%	67.47%	67.47%	67.47%	67.47%	67.47%	67.47%
FIIs	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
DIIs	7.48%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Public	0.00%	32.53%	32.53%	32.53%	32.53%	32.53%	32.53%	32.53%	32.53%	32.53%	32.53%
Total Shareholders	21	978	921	873	832	825	966	997	1,022	998	991

Market Transactions

Unlock Premium Features

Analyst Target, Price, EPS and Revenue Projections

Upgrade

Projection

Documents

Presentations

Concalls

Reports

Presentations

No documents found!

Actions

Action Type

‌
‌

Announcements

Last 7 days

Newest

Sentiment

Rights Issue

2 days ago

Record date set for 1:1 Rights Issue on March 10, 2026

JFL Life Sciences Ltd. has fixed March 10, 2026 as the record date to determine shareholders eligible for a 1 (one) fully paid rights equity share for every 1 existing equity share.

Rights Issue

2 days ago

Board approves 1:1 Rights Issue totalling Rs.3,299.53 lakhs

Board approved a 1:1 rights issue of 3,29,95,323 equity shares at Rs.10/share (aggregate Rs.3,299.53 lakhs); Record Date Mar 10, 2026; issue opens Mar 16 and closes Mar 24, 2026 (may be extended).

Rights Issue

2 days ago

Board approves 1:1 Rights Issue of 3.29 Cr Shares at Rs.10

Board approved a 1:1 rights issue of 3,29,95,323 equity shares at Rs.10 each (aggregate Rs.3,299.53 lakh), record date Mar 10, 2026; issue opens Mar 16 and closes Mar 24, 2026 (may be extended).

AI Mode

Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.

Ask AI

Frequently Asked Questions about JFL Life Sciences Ltd

JFL Life Sciences Ltd (JFLLIFE) is currently trading at 10.95 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.

JFL Life Sciences Limited, established in 2010, specializes in the manufacturing and marketing of pharmaceutical products, including dry powder injections and various tablets and capsules. The company has a wide reach with its products distributed across India and exported to 10 countries, including parts of Africa, the Middle East, and CIS nations. JFL Life Sciences has a robust R&D infrastructure and an FDA-approved manufacturing facility near Ahmedabad, enhancing its competitive edge in the pharmaceutical sector. Through its IPO in August 2022, JFL Life Sciences raised approximately Rs. 18.16 Crore, aiding its expansion and financial strategy. The company is strategically registered with health ministries in several countries and uses a stringent quality assurance process for its manufacturing stages.

Over the past 52 weeks, JFL Life Sciences Ltd has traded between a low of ₹10.00 and a high of ₹22.20. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.

JFL Life Sciences Ltd has a market capitalization of approximately 36.13. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.

JFL Life Sciences Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 7.55 and operates in the Pharmaceuticals sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.

Based on its market capitalization of 36.13 Cr, JFL Life Sciences Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.

JFL Life Sciences Ltd operates in the Pharmaceuticals sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.

The Price-to-Earnings (PE) ratio of JFL Life Sciences Ltd is 7.55. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.

Jfl Life Sciences Ltd

Stock Summary and Key Metrics

Investment Checklist

Investment Checklist

Overview

Financial Ratios

Technicals

Forecasts

Peers

Price Chart Comparison